Project Grant R01DK140365
- Grant Award Summary This Project Grant, awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports basic biomedical research investigating the role of ciliary Hedgehog (HH) signaling in hypothalamic tanycyte proliferation and energy homeostasis regulation. The research is being conducted at Indiana University Indianapolis and aims to elucidate mechanisms...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases awarded a $705,817 Project Grant to the University of California, Irvine on July 21, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research on differential spatial cyclic adenosine monophosphate (cAMP) signaling in pancreatic beta cells through April 30, 2029. The research investigates how pancreatic beta cells interpret cAMP signaling...
- Grant Award Summary The Beckman Research Institute of the City of Hope received a $847,746 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for the five-year period commencing September 1, 2025 through August 31, 2030. The research project, titled "Role of UPR Transducer XBP1 in Pancreatic Beta Cell Survival and Function Under Metabolic Stress,"...
- Award Summary Weill Medical College of Cornell University received a $770,603 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective March 1, 2026, through February 28, 2031. The research focuses on elucidating GIP (glucose-dependent insulinotropic polypeptide) receptor signaling mechanisms through investigation of a human genetic variant (GIPR-Q354)...
- Federal Grant Award Summary Yale University received a $1.33M Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for the period June 1, 2025 through May 31, 2029. The award funds basic biomedical research investigating the compensatory mechanisms by which pancreatic alpha-cells (A-cells) preserve insulin secretion and glycemic control in response to...
- Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Baylor College of Medicine a Project Grant of $123,908.00 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective June 1, 2025, through March 31, 2030. This research project investigates the role of the ANO4 ion channel in the area postrema (AP) region of the brain and its requirement for the orexigenic (appetite-stimulating) effects of asprosin,...
- Federal Project Grant Award Summary The Beckman Research Institute of the City of Hope received a $153,554 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 15, 2025. The award supports research through July 31, 2030, and funds a project titled "Alpha Cell Heterogeneity: Unveiling Novel Targets for T1D Therapy." The research...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $672,737 Project Grant to the University of California, Los Angeles (UCLA) effective August 15, 2025, through July 31, 2030, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This research initiative investigates the molecular mechanisms underlying dysregulated insulin secretion in obesity, specifically examining the role of...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $706,199 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 21, 2025, with completion targeted for June 30, 2030. The award funds research to elucidate the role of NAD+ (nicotinamide adenine dinucleotide) metabolism in obesity-induced pancreatic...
- Federal Project Grant Award Summary Mayo Clinic received a $2.33M project grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 4, 2025, through August 31, 2029. The research initiative investigates the molecular mechanisms underlying the crosstalk between extracellular vesicles (EVs) and autophagy pathways in Type 2 Diabetes (T2D)...
METABOLIC SIGNALING OF THE BETA CELL PRIMARY CILIUM - PROJECT SUMMARY PRIMARY CILIA SERVE AS CELLULAR SENSORS FOR RAPID DETECTION OF ENVIRONMENTAL CHANGES. THESE MICROTUBULE- BASED ANTENNAE ARE EXPRESSED ON ALMOST ALL EUKARYOTIC CELLS ACROSS UNICELLULAR AND MULTICELLULAR SYSTEMS AND ENCOMPASS WIDE ROLES IN DEVELOPMENT AND HOMEOSTASIS. IN RECENT YEARS, PRIMARY CILIA HAVE COME INTO THE LIMELIGHT IN DIABETES AND METABOLISM RESEARCH, AS PREVIOUSLY UNAPPRECIATED FUNCTIONS HAVE BEEN ATTRIBUTED TO THESE ORGANELLES ON ENDOCRINE CELLS. RECENT HUMAN GENETIC AND GWAS STUDIES SHOW THAT CILIA HAVE CLINICALLY IMPORTANT ROLES IN METABOLIC DISEASES INCLUDING OBESITY AND DIABETES. IN THE PANCREATIC ISLET, WE OBSERVE THAT LOSS OF CILIA DISRUPTS B-CELL ENDOCRINE FUNCTIONS INCLUDING GLUCOSE-STIMULATED CA2+ SIGNALING AND INSULIN SECRETION. MICE LACKING CILIA ON B-CELLS DEVELOP GLUCOSE INTOLERANCE AND DIET-INDUCED DIABETES. THESE FINDINGS SUGGEST THAT PRIMARY CILIA MEDIATE GLUCOSE RESPONSIVENESS IN NORMAL B-CELLS, BUT THE MOLECULAR DRIVERS OF CILIARY GLUCOSE- SENSING AND SIGNALING ARE UNKNOWN. IN ADDITION, PROTEOME AND METABOLOME PROFILING HAVE BEEN DONE IN OTHER MAMMALIAN CILIA BUT NOT IN PANCREATIC ISLET B-CELLS, POSING A KNOWLEDGE GAP REGARDING CILIA-DEPENDENT REGULATORY MECHANISMS IN B-CELL GLUCOSE METABOLISM AND SECRETORY FUNCTION. OUR PRELIMINARY STUDIES IDENTIFY GLYCOLYTIC SIGNALING MACHINERY IN B-CELL CILIA, BOTH BY PROTEOMICS AND WITH A PALETTE OF NEWLY DEVELOPED BIOSENSORS THAT MONITOR THE DYNAMICS OF CILIARY SIGNALING. WE FURTHER DEMONSTRATE THAT GLYCOLYTIC FLUXES DIFFER BETWEEN PRIMARY CILIA AND CYTOSOL IN B-CELLS. BASED ON THESE FINDINGS, WE HYPOTHESIZE THAT COMPARTMENTALIZED GLUCOSE METABOLISM IN B-CELL CILIA GENERATES SIGNALS THAT REGULATE CILIARY AND CELLULAR FUNCTION. TO TEST THIS HYPOTHESIS, WE WILL COMBINE GENETIC LOSS-OF-FUNCTION MODELS WITH STATE-OF-THE-ART PROTEOMIC AND METABOLIC PROFILING TOOLS, MICROSCOPY, ELECTROPHYSIOLOGICAL RECORDINGS, AND ISLET FUNCTION TESTS TO DELINEATE THE MECHANISMS BY WHICH CILIA EFFECT GLUCOSE-DEPENDENT B-CELL FUNCTIONAL CHANGES. AIM 1 WILL LEVERAGE STRONG FUNCTIONAL IMAGING, PROTEOMIC, AND METABOLOMICS EXPERTISE AND PROMISING PILOT DATA TO DELINEATE THE SIGNALING NETWORK BY WHICH PRIMARY CILIA RELAY GLYCOLYTIC INFORMATION AND TO COMPREHENSIVELY IDENTIFY CILIARY SIGNALING PATHWAYS RELEVANT TO B- CELL FUNCTION. AIM 2 WILL DETERMINE THE MECHANISMS BY WHICH CILIA REGULATE B-CELL ELECTROPHYSIOLOGICAL PROPERTIES AND INTRACELLULAR METABOLIC CROSSTALK LEADING TO INSULIN SECRETION. A DETAILED UNDERSTANDING OF THESE REGULATIONS BY PRIMARY CILIA COULD SUPPORT THE DEVELOPMENT OF NOVEL THERAPIES TO MODULATE B-CELL FUNCTION IN DIABETES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $658.9k | 7/18/25 | ||
| Not listed | $0 | 7/17/25 | ||
| Not listed | $619.4k | 5/31/24 |